Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Conference Steering Committee

Research output: Contribution to journalArticlepeer-review

39 Scopus citations
Original languageEnglish (US)
Pages (from-to)231-234
Number of pages4
JournalKidney international
Volume94
Issue number2
DOIs
StatePublished - Aug 2018

Funding

CW declared having received consultancy fees from Boehringer Ingelheim, GlaxoSmithKline, and Sanofi Genzyme; speaker honorarium from Boehringer Ingelheim, Merck Sharpe & Dohme, and Sanofi Genzyme; and research support from Sanofi Genzyme. CAH declared having received consultancy fees from AbbVie, FibroGen, KBP Biosciences, OxThera, and Relypsa; equity ownership/stock options on Boston Scientific, Bristol-Myers Squibb, General Electric, Johnson & Johnson, and Merck; and research support from Amgen, National Institutes of Health, Relypsa, and Zoll. CAH also expects future consultancy roles from AstraZeneca, Boehringer Ingelheim, Corvidia, and Sanifit. MPT declared having received consultancy fees from Abbott, iBeat, iRhythm, Medtronic, and Precision Health Economics; equity ownership/stock options on AliveCor and iBeat; speaker honorarium from Abbott and Medtronic; and research support from American Heart Association, Apple, Cardiva Medical, and Veterans Health Administration.

Keywords

  • arrhythmia
  • atrial fibrillation
  • chronic kidney disease
  • stroke
  • sudden cardiac death

ASJC Scopus subject areas

  • Nephrology

Cite this